Full-Time
Posted on 12/21/2024
Biotechnology focused on cell rejuvenation research
$215.9k - $292.1kAnnually
Senior
San Diego, CA, USA
UK Citizenship Required
You match the following Altos Labs's candidate preferences
Employers are more likely to interview you if you match these preferences:
Altos Labs specializes in biotechnology with a focus on cell rejuvenation, aiming to restore cell health and resilience to reverse diseases and injuries. They utilize cellular rejuvenation programming to enhance cells' ability to resist stressors that lead to illness. Unlike competitors, Altos Labs emphasizes scientific research and collaboration with healthcare providers and pharmaceutical companies to develop breakthrough treatments. Their goal is to improve patients' quality of life by providing effective solutions for various health conditions.
Company Size
501-1,000
Company Stage
Seed
Total Funding
$3.2B
Headquarters
Los Altos, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
In London, Altos recently launched its inaugural Margarita Masters competition for bartenders, with the hope of taking it nationwide in the future.
«Per uno scienziato Elon Musk ha senz’altro meno appeal di un Premio Nobel». Se poi i Nobel sono quattro, tutti seduti nel board of directors della startup per cui lavori, potremmo dire non esserci partita. Tra questi, ad esempio, Jennifer Doudna, che ha vinto grazie al lavoro sull’editing genetico Crispr nel 2020. Simone Bianco, employee numero 27 di Altos Labs con sede a San Francisco, è Principal Investigator e Director of Computational Biology in quella che lui preferisce definire una venture, non una startup. Nel corso dell’intervista gli abbiamo chiesto di Musk e dei suoi piani per salvare l’umanità, anche con Neuralink, ma la discussione ha rapidamente virato verso altre figure, più specializzate nella materia in questione. Altos Labs, dunque
If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one of our readers – they would want to live forever, yet only if they stayed young. Among others, living long worries people as it is associated with getting old and suffering from various diseases.Yet if technology allows us to extend our life spans it will also likely improve our health spans. According to demographers, children today have a better chance of living up to 100 years old than ever before. But their lives won’t be just longer, they will also benefit from day-to-day technological advances aimed at improving their well-being, preventing diseases, and keeping their minds and bodies in shape.Slowing aging presents an economic opportunity, too. In the US, an estimate shows that just one to two years increase in life expectancy are worth between $7 trillion and $38 trillion
Hans Bishop and Steve Harr know a few things about biotech. The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr was COO and CFO.
After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%. | 2021 marked the second consecutive year of record-breaking private financing for biotechs, with more than $28 billion raised. The total haul is a 26% increase from 2020, and the stunning dollar amounts came even as the public market depreciated throughout the year. Here's our look at the 10 biotechs that raked in the largest VC investments.